Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Mediwound Ltd Ord Sh
(NQ:
MDWD
)
16.98
-0.31 (-1.79%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Mediwound Ltd Ord Sh
< Previous
1
2
3
4
5
Next >
MediWound Announces Collaboration with Mölnlycke on EscharEx® Phase III Study
August 15, 2023
MediWound joins forces with one of the largest global chronic wound companies in pivotal study for patients with venous leg ulcers
From
MediWound Ltd.
Via
GlobeNewswire
MediWound Announces Collaboration with MIMEDX on EscharEx® Phase III Study
August 15, 2023
MediWound to join forces with leading chronic wound allograft company in pivotal study for patients with venous leg ulcers
From
MediWound Ltd.
Via
GlobeNewswire
Earnings Outlook For MediWound
August 14, 2023
Via
Benzinga
MediWound to Report Second Quarter 2023 Financial Results
August 07, 2023
Conference Call and Webcast Scheduled for Wednesday, August 16th at 8:30 am Eastern Time
From
MediWound Ltd.
Via
GlobeNewswire
Recap: MediWound Q1 Earnings
May 30, 2023
Via
Benzinga
Earnings Outlook For MediWound
May 29, 2023
Via
Benzinga
5 Analysts Have This to Say About MediWound
March 17, 2023
Via
Benzinga
MediWound Announces Commercial Launch of NexoBrid® in Japan
August 01, 2023
Kaken Pharmaceutical launches NexoBrid under an exclusive marketing and distribution agreement
From
MediWound Ltd.
Via
GlobeNewswire
3 Micro-Cap Stocks to Buy for Multibagger Returns
July 11, 2023
These are the micro-cap stocks to buy and they represent companies with decent fundamentals and visibility for robust growth.
Via
InvestorPlace
MediWound Announces Positive Results in Its U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma
July 10, 2023
From
MediWound Ltd.
Via
GlobeNewswire
MediWound Receives Positive Scientific Advice from European Medicine Agency (EMA) on EscharEx Phase III Study Design
July 03, 2023
Affirms the clear path forward for the Company’s global Phase III study of EscharEx in venous leg ulcers
From
MediWound Ltd.
Via
GlobeNewswire
Preview: MediWound's Earnings
March 15, 2023
Via
Benzinga
Cowen & Co. Maintains Outperform Rating for MediWound: Here's What You Need To Know
December 30, 2022
Via
Benzinga
FDA Approves MediWound's NexoBrid For Burn Treatment
December 30, 2022
Via
Benzinga
MediWound to Participate in Fireside Chat at Maxim Group Healthcare Virtual Conference 2023
June 14, 2023
From
MediWound Ltd.
Via
GlobeNewswire
Earnings Scheduled For May 30, 2023
May 30, 2023
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is projected to report earnings for its first quarter.
Via
Benzinga
MediWound Reports First Quarter 2023 Financial Results and Provides a Company Update
May 30, 2023
From
MediWound Ltd.
Via
GlobeNewswire
MediWound to Report First Quarter 2023 Financial Results
May 12, 2023
Conference Call and Webcast Scheduled for Tuesday, May 30th at 8:30 am Eastern Time
From
MediWound Ltd.
Via
GlobeNewswire
MediWound Announces an Additional $10 Million Award from BARDA
May 09, 2023
Funding to support emergency stockpiling replenishment, pediatric indication submission, and expanded access treatment protocol extension
From
MediWound Ltd.
Via
GlobeNewswire
MediWound to Present Phase 2 EscharEx® Data at the Symposium on Advanced Wound Care (SAWC) Spring 2023
April 26, 2023
From
MediWound Ltd.
Via
GlobeNewswire
MediWound Reports Fourth Quarter and Full Year 2022 Financial Results and Company Update
March 16, 2023
From
MediWound Ltd.
Via
GlobeNewswire
MediWound Announces the Appointment of Hani Luxenburg as Chief Financial Officer
March 16, 2023
From
MediWound Ltd.
Via
GlobeNewswire
MediWound Expands its Global Leadership Team to Help Drive Company’s Future Growth
March 06, 2023
From
MediWound Ltd.
Via
GlobeNewswire
MediWound to Report Fourth Quarter and Year-End 2022 Financial Results
March 02, 2023
Conference Call and Webcast Scheduled for Thursday, March 16 at 8:30 am Eastern Time
From
MediWound Ltd.
Via
GlobeNewswire
MediWound to Present Corporate Highlights at Upcoming Investor Conferences
February 23, 2023
From
MediWound Ltd.
Via
GlobeNewswire
MediWound Announces Closing of $27.5 Million Registered Direct Offering of Ordinary Shares
February 07, 2023
From
MediWound Ltd.
Via
GlobeNewswire
MediWound Announces $27.5 Million Registered Direct Offering of Ordinary Shares Priced At-The-Market
February 03, 2023
From
MediWound Ltd.
Via
GlobeNewswire
Starbucks To Rally 11%? Here Are 10 Other Analyst Forecasts For Wednesday
January 04, 2023
UBS cut Microsoft Corporation (NASDAQ: MSFT) price target from $300 to $250. UBS analyst Karl Keirstead downgraded the stock from Buy to Neutral. Microsoft shares fell 2% to $234.73 in pre-market...
Via
Benzinga
MediWound Announces FDA Approval of NexoBrid® for the Treatment of Severe Thermal Burns in Adults
December 29, 2022
From
MediWound Ltd.
Via
GlobeNewswire
Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors
December 27, 2022
Biopharma stocks were not immune to the broader market downturn seen for much of 2022.
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.